Edward M. Chan - Concepedia

Author

Edward M. Chan

Also Known As

E Chan, E. Chan, E. M. Chan, E. Michael Chan, Edward Chan, Edward M Chan, Edward M. Chan, Edward Michael Chan, Edward m Chan, Eli Chan,

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Massachusetts General Hospital Dana-Farber Cancer Institute Harvard University South Texas Accelerated Research Therapeutics

About

Edward M. Chan is an author at Eli Lilly (United States) specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	16	694
2	Cell Biology	11	11	532
3	Health Sciences	4	4	87
4	Natural Sciences	2	2	65
5	Allergy	1	1	15

Edward M. Chan

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors Amita Patnaik, Lee S. Rosen, Sara M. Tolaney, Cancer Discovery	2016	740
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine Lawrence M. Gelbert, Shufen Cai, Xi Lin, Investigational New Drugs	2014	555
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer Amita Patnaik, Paul Haluska, Anthony W. Tolcher, Clinical Cancer Research	2015	137
The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation Vipin Yadav, Teresa F. Burke, Lysiane Huber, Molecular Cancer Therapeutics Drug TargetPharmacotherapyB-raf Selective InhibitorsTumor BiologyCyclin D1 Upregulation	2014	134
Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts Sonya C. Tate, Shufen Cai, Rose T. Ajamie, Clinical Cancer Research	2014	126
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial Nizar J. Bahlis, Caitlin Costello, Noopur Raje, Nature Medicine	2023	122
Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Robert M. Campbell, Bryan D. Anderson, Nathan A. Brooks, Molecular Cancer Therapeutics Drug TargetAntitumor ActivityP38 MapkPharmacotherapyCancer Biology	2013	115
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer Shubham Pant, Suzanne F. Jones, Carla Kurkjian, European Journal of Cancer	2016	89
A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients Sonya C. Tate, Amanda K. Sykes, Palaniappan Kulanthaivel, Clinical Pharmacokinetics	2017	68
A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. Geoffrey I. Shapiro, Lee S. Rosen, Anthony W. Tolcher, Journal of Clinical Oncology Chemoprevention StrategyFirst-in-human PhasePathologyGliomaTumor Biology	2013	66

Page 1